TrialThe Journal of infectious diseases2015

Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286.

Allan R Tenorio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.